After taking Lenvatinib for three years, there is still no resistance

Resistance is a common drug treatment problem that may affect some patients. Because everyone responds differently to medications, it may take longer for some people to develop resistance. Although the patient has been taking Lenvatinib for three years, the lack of resistance may be a positive sign. If patients are concerned about drug resistance, it is recommended to communicate with their doctors, who can assess the condition and provide recommendations based on an individualized treatment plan.

Lenvatinibis a multi-target tyrosine kinase inhibitor (TKI) and one of the first-choice targeted drugs for the treatment of advanced hepatocellular carcinoma (aHCC). Since the REFLECT study showed that lenvatinib is not inferior to sorafenib in terms of overall survival (OS), lenvatinib monotherapy is widely used in advanced hepatocellular carcinoma. In addition, lenvatinib combination therapy, especially the combination of lenvatinib and immune checkpoint inhibitors (ICIs), has shown more encouraging clinical results. However, drug development and comprehensive treatment have not significantly improved the prognosis. Lenvatinib resistance is often encountered during treatment, but the underlying molecular mechanism of resistance remains unclear.

LenvatinibThe original drug has been launched in China and is covered by Class B medical insurance. The price of each box may be more than 3,000 yuan. The original drug Lenvatinib currently on the market overseas may cost more than RMB 1,000 per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of each box produced by a Bangladeshi pharmaceutical factory may be RMB 800 (the price may fluctuate due to exchange rates).